Clinical trial
A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant…
NCT00289016 · BioVex Limited, Industry · Completed
Key facts
| NCT number | NCT00289016 |
|---|---|
| Title | A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma |
| Official title | A Phase II Study of the Efficacy, Safety and Immunogenicity of OncoVEX^GM-CSF in Patients With Stage IIIc and Stage IV Malignant Melanoma |
| Lead sponsor | BioVex Limited, Industry |
| Collaborators | Symbion Research International Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Drug |
| Interventions | Talimogene Laherparepvec |
| Enrollment | 50 |
| Start date | Dec 1, 2005 |
| Primary completion | Dec 1, 2008 |
| Completion | May 1, 2009 |
| First posted | Feb 9, 2006 |
| Last update posted | Dec 18, 2015 |
| Countries | United Kingdom, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: